Evaluation of therapy with methanol extraction residue of BCG (MER).
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D009169:Mycobacterium tuberculosis / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; C011499:methanol extraction residue (MER) tubercle bacillus fraction